Product information and disease descriptionProduct descriptionProduct information
Product comparison
8 evidence topics · 8 sources
Head-to-head and indirect comparisons of AD109 with other OSA treatments
No evidence found.
Cross-trial context for AD109 and tirzepatide in an editorial on SynAIRgy
Comparator: tirzepatide in moderate-to-severe OSA with obesity, AHI with 4% desaturation hypopnea rule
“which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review comparison of OSA pharmacotherapies, SynAIRgy figures under the treatment policy estimand
“Although AD109 demonstrated statistically significant therapeutic efficacy compared with placebo, the reductions in the AHI and oxygen desaturation index were only 3.3/h and 3.7/h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that long-term tolerability and safety may remain challenging [28].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although tirzepatide is currently the only U.S. Food and Drug Administration-approved medication for OSA, it is expected that OSA-directed pharmacotherapy unrelated to weight loss that is effective for patients who refuse or discontinue PAP therapy may become available in the near future.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote